Diba Latifi

Diba Latifi is a Researcher in the Department of Surgery at Erasmus MC, specializing in pancreatic cancer immunology and therapeutic interventions. Her work bridges clinical oncology, immunotherapy, and translational research with significant focus on B cell dynamics and novel treatment combinations.

Her research interests center on pancreatic cancer microenvironment, B cell immunology, and innovative therapeutic approaches including stereotactic radiation, Rintatolimod pharmacology, and cancer vaccines. She investigates how dysbiosis in vermiform appendixes correlates with pancreatic cancer progression and how immunomodulators can enhance treatment efficacy.

Analysis of her publication trends reveals strong emphasis on translational oncology with recurring themes in combination therapies (radiation + immunotherapy), B cell modulation, and drug repurposing. Her work frequently addresses locally advanced/metastatic pancreatic cancer through clinical trials and mechanistic studies, showing particular interest in bridging virology and oncology as seen in her SARS-CoV-2 related research.

Her scientific contributions include participation in multicenter trials (Dutch Pancreatic Cancer Group) and named patient programs, with publications appearing in high-impact journals including Frontiers in Immunology, Cancers, and Radiotherapy and Oncology.

Latifi collaborates extensively with surgical oncology teams and immunology researchers at Erasmus MC, particularly with C.H.J. van Eijck's group. Her work demonstrates strong integration of clinical practice with laboratory research, focusing on improving survival outcomes for pancreatic cancer patients through novel immunological approaches.